Enjoy complimentary customisation on priority with our Enterprise License!
The ophthalmoplegia market size is forecast to increase by USD 435.8 million at a CAGR of 6% between 2023 and 2028. Ophthalmoplegia is a neurological condition characterized by lateral eye movement abnormalities, resulting in double vision, blurred vision, or muscle weakness. The condition can be congenital or associated with systemic disorders, such as multiple sclerosis and other neurological diseases. The global ophthalmoplegia market is experiencing significant growth due to the increasing incidence of neurological disorders and the limited treatment options available. The aging population is another contributing factor, as geriatrics are more susceptible to neurological disorders. Despite advancements in medical technology, there remains a need for effective and accessible treatments for ophthalmoplegia. This market analysis report provides an in-depth examination of market growth drivers, trends, and challenges. It highlights the impact of the increasing geriatric population and the rising incidence of neurological disorders on market growth. Additionally, the report explores the limited treatment options for ophthalmoplegia and the potential opportunities for innovation in this field.
Ophthalmoplegia refers to the weakness or paralysis of the eye muscles, leading to impaired eye movement. This condition can be caused by various factors, including nerve damage, muscle disorders, systemic conditions, and genetic mutations. The market for ophthalmoplegia is witnessing significant growth due to the increasing prevalence of eye muscle disorders and the need for effective diagnostic tools and treatment options. Ophthalmoplegia can be categorized into external and internal forms. External ophthalmoplegia is characterized by weakness of the extraocular muscles, resulting in limited eye movement. On the other hand, internal ophthalmoplegia is caused by damage to the cranial nerves, leading to impaired function of the oculomotor nerve, trochlear nerve, abducens nerve, superior rectus, and inferior rectus muscles. The symptoms of ophthalmoplegia include eye weakness, double vision, pupil constriction, and difficulty adjusting the lens. Diagnosis of ophthalmoplegia involves a multidisciplinary approach, including clinical examinations, imaging studies, blood tests, electromyography (EMG), and biopsies. The treatment for ophthalmoplegia depends on the underlying cause.
Simultaneously, symptomatic management includes medications for muscle relaxants, botulinum toxin injections, and prism glasses. Surgical interventions may be necessary for severe cases to improve eye alignment and function. Quality of life for patients with ophthalmoplegia can be significantly improved with proper diagnosis and treatment. The increasing prevalence of eye muscle disorders, the need for accurate diagnosis, and the availability of advanced treatment options are driving the growth of the ophthalmoplegia market. The market is also witnessing significant research and development efforts to develop new diagnostic tools and therapies for ophthalmoplegia. Ophthalmoplegia is a complex condition that affects the function of the eye muscles and can lead to significant visual impairment. The market for ophthalmoplegia is witnessing significant growth due to the increasing prevalence of eye muscle disorders and the need for effective diagnostic tools and treatment options. A multidisciplinary approach, including clinical examinations, imaging studies, blood tests, electromyography (EMG), and biopsies, is essential for accurate diagnosis and effective treatment of ophthalmoplegia. The market is expected to continue growing due to the ongoing research and development efforts in this field.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The hospitals segment is estimated to witness significant growth during the forecast period. The global ophthalmoplegia market primarily caters to hospitals as the leading end-users due to their role as major diagnostic and treatment centers for eye movement disorders. Hospitals, particularly large tertiary care centers and academic medical institutions, are well-equipped with advanced diagnostic tools, specialized ophthalmology departments, and skilled healthcare professionals. These facilities offer comprehensive care for various ophthalmoplegia cases, ranging from simple to complex, requiring multidisciplinary approaches and intricate treatments.
Get a glance at the market share of various segments Download the PDF Sample
The hospitals segment was valued at USD 723.60 million in 2018. The presence of specialized neurologists, ophthalmologists, and supporting medical staff in hospitals enables effective management of both acute and chronic eye muscle disorders, such as external ophthalmoplegia and internal ophthalmoplegia. Patients benefit from a range of therapeutic interventions, including medication administration, surgical procedures, and rehabilitation services. Hospitals' well-established infrastructure supports the delivery of these interventions, making them the preferred choice for managing disorders affecting eye muscles, eye movement, pupil constriction, and lens adjustment.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
In North America, the ophthalmoplegia market is experiencing substantial growth due to several key factors. The region's advanced healthcare infrastructure, characterized by high healthcare expenditures and modern medical facilities, fosters market expansion. Leading pharmaceutical companies and research institutions in the region drive continuous innovation in treatment options and diagnostic technologies. Moreover, the high level of awareness among healthcare providers and patients in North America, along with comprehensive insurance coverage policies, results in increased diagnosis rates and higher adoption of treatment protocols. The presence of a well-established network of specialized neuro-ophthalmology centers and a skilled healthcare workforce ensures the delivery of high-quality patient care. Cranial nerves, including the oculomotor nerve, trochlear nerve, and abducens nerve, play a crucial role in eye movement. Superior rectus muscle dysfunction can lead to ophthalmoplegia, causing various symptoms such as diplopia and ptosis. Effective treatment and symptom relief are essential for improving the quality of life for those affected. In North America, the focus on research and development, coupled with the availability of advanced diagnostic tools and therapeutic interventions, positions the region at the forefront of ophthalmoplegia market growth.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing geriatric population is notably driving market growth. The aging population is a major factor fueling the growth of the ophthalmoplegia market. By 2030, it is estimated that one in six individuals worldwide will be aged 60 years or older, representing a significant increase from the current population of one billion. This demographic trend is projected to continue, with the number of people in this age group reaching 1.4 billion by 2030 and doubling to 2.1 billion by 2050. The population aged 80 years or older is also anticipated to triple, rising from current figures to 426 million by mid-century.
Furthermore, this substantial growth in the elderly population is leading to an increased demand for treatments related to ophthalmoplegia, a condition characterized by weakness or difficulty controlling the muscles responsible for coordinating eye movement, including the inferior rectus and causing symptoms such as drooping eyelids. This condition can affect the nerves that control eye movements, leading to conditions like internuclear ophthalmoplegia. The rising prevalence of this condition, particularly in the aging population, is driving market growth. Thus, such factors are driving the growth of the market during the forecast period.
The increasing incidence of neurological disorders is the key trend in the market. Neurological conditions, including trauma, infarction, mitochondrial diseases, migraines, thyroid disease, stroke, and brain injury, are on the rise and significantly impacting the global ophthalmoplegia market. According to a major study published by the World Health Organization (WHO) in 2021, over 3 billion people worldwide live with a neurological condition, making it the leading cause of illness and disability globally.
Moreover, neurological disorders, such as multiple sclerosis, stroke, and brain tumors, can result in ophthalmoplegia, a condition characterized by weakness or paralysis of the eye muscles. With the increasing prevalence of these disorders, there is a growing demand for specialized medical devices and treatments to manage eye movement disorders. This trend is expected to continue as the number of individuals affected by neurological conditions continues to rise. Thus, such trends will shape the growth of the market during the forecast period.
The limited treatment options for ophthalmoplegia is the major challenge that affects the growth of the market. The ophthalmoplegia market in the United States is marked by a notable lack of effective treatment options, posing considerable challenges for both patients and market growth. The current therapeutic landscape primarily consists of corticosteroids, immunosuppressants, and surgical procedures. While these treatments can provide some relief, they may not adequately address the diverse forms of ophthalmoplegia or cater to patients with rare conditions or those unresponsive to standard therapies. This scarcity of treatment alternatives results in inadequate management of the condition, leading to increased patient dissatisfaction and escalating healthcare expenses.
However, ophthalmoplegia is a neurological condition that affects lateral eye movement, causing symptoms such as double vision and blurred vision. It can be congenital or associated with systemic disorders, including multiple sclerosis. The limited treatment options available exacerbate the challenges faced by patients and healthcare providers in managing this condition effectively. In the US, the ophthalmoplegia market requires innovative solutions to address the unmet medical needs of patients. The development of novel therapeutic approaches, such as gene therapy and stem cell treatments, holds promise in improving patient outcomes and expanding market opportunities. These advanced treatments could potentially address the root causes of ophthalmoplegia and provide more personalized and effective care for patients. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers ophthalmoplegia medications such as LUMIGAN, COMBIGAN, and others.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Ophthalmoplegia, a condition characterized by weakness or paralysis of the eye muscles, affects various extraocular muscles that control eye movement, pupil constriction, and lens adjustment. External ophthalmoplegia and internal ophthalmichegia are two types, with external affecting the muscles around the eyes, causing drooping eyelids and difficulty controlling muscles, while internal ophthalmoplegia affects nerve fibers and cranial nerves, leading to weakness, double vision, and blurred vision. Causes of ophthalmoplegia include nerve damage from systemic conditions, genetic mutations, mitochondrial dysfunction, and muscle disorders. Conditions such as multiple sclerosis, trauma, infarction, mitochondrial diseases, migraines, thyroid disease, stroke, brain injury, and brain tumor can lead to ophthalmoplegia.
Furthermore, diagnosing ophthalmoplegia requires a multidisciplinary approach, including clinical examinations, imaging studies, blood tests, electromyography (EMG), and biopsies. Symptomatic management and surgical interventions aim to improve quality of life and provide symptom relief. The six cranial nerves, including the oculomotor nerve, trochlear nerve, abducens nerve, superior rectus, and inferior rectus, play crucial roles in eye movement. Damage to these nerves can result in weakness, difficulty coordinating eyes, and lateral eye movement issues. Ophthalmoplegia can significantly impact daily life, leading to challenges in performing routine tasks and maintaining visual acuity. Understanding its causes and available treatments is essential for managing this complex condition.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
195 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 6% |
|
Market growth 2024-2028 |
USD 435.8 million |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
5.3 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 44% |
|
Key countries |
US, Germany, Japan, UK, France, India, Brazil, Canada, Australia, and Italy |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
AbbVie Inc., Agnitio Pharma, Atom Pharma, Care Formulation Labs Pvt Ltd, Cellera Farma, Deutsche Pharma Laboratories, FarmaSyn SA, GlaxoSmithKline Plc, Innovative Pharmaceuticals Pvt Ltd, Medytox, Merz Pharma GmbH and Co KGaA, Novartis AG, Orchidia Pharmaceutical Industries, Pfizer Inc., Sally Pharmacies, and Symbiotec Pharmalab Pvt. Ltd |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by End-user
9 Market Segmentation by Product Type
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
